ARTICLE | Company News
Implicit Bioscience Pty. Ltd., U.S. Department of Defense infectious news
October 29, 2007 7:00 AM UTC
Implicit will receive $16.3 million over 37 months from the DoD to develop oglufanide (IM862) to treat intracellular bacterial diseases, including melioidosis, a type of pneumonia. The dipeptide immun...